NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France
ALPHE
PHIBRO ANIMAL HEALTH CORP Logo
Develops animal health products, vaccines, and nutrition for livestock and companion animals.
United States of America
PAHC
Philogen Logo
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
Italy
PHIL
Phio Pharmaceuticals Corp. Logo
Developing RNAi-based immuno-oncology therapeutics for melanoma and other skin cancers.
United States of America
PHIO
Phoenix Asia Holdings Ltd Logo
A subcontractor for substructure projects and a large-scale manufacturer of fine chemicals & APIs.
United States of America
PHOE
Photocure ASA Logo
Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.
Norway
PHO
Pierrel Logo
Global pharma company specializing in dental anesthetics and contract manufacturing services.
Italy
PRL
PLIANT THERAPEUTICS, INC. Logo
Developing novel integrin-based therapies for fibrosis and related diseases.
United States of America
PLRX
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea
222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel
PLUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.